Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tumor infiltrating lymphocytes LN-145-S1

A proprietary preparation of autologous tumor infiltrating lymphocytes (TILs), with potential immunomodulating and antineoplastic activities. The autologous TILs are isolated from an autologous tumor sample and expanded ex vivo in the presence of interleukin-2 (IL-2). Upon infusion of the autologous TILs LN-145-S1 back into the patient, the cells specifically recognize, target and kill the patient's tumor cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous TILs LN-145-S1
autologous tumor-infiltrating lymphocytes LN-145-S1
LN145-S1
Code name:LN 145-S1
LN-145-S1
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search